{
  "metadata": {
    "version": "1.0",
    "last_updated": "2026-01-15",
    "sources": ["NCCN Guidelines", "ASCO Guidelines", "ESMO Guidelines"],
    "category": "Non-Small Cell Lung Cancer Treatment Guidelines"
  },
  "guidelines": [
    {
      "guideline_id": "GL-NSCLC-001",
      "title": "NSCLC Stage-Based Treatment Overview",
      "source": "NCCN NSCLC Guidelines v1.2026",
      "category": "Treatment",
      "keywords": [
        "NSCLC",
        "staging",
        "treatment",
        "surgery",
        "radiation",
        "chemotherapy"
      ],
      "stages": {
        "Stage I-II": {
          "recommendation": "Surgical resection is preferred for operable patients",
          "alternatives": [
            "SBRT for medically inoperable",
            "Adjuvant chemotherapy for high-risk Stage II"
          ]
        },
        "Stage III": {
          "recommendation": "Concurrent chemoradiation for unresectable disease",
          "alternatives": [
            "Surgery followed by adjuvant therapy for resectable",
            "Durvalumab consolidation after chemoRT"
          ]
        },
        "Stage IV": {
          "recommendation": "Systemic therapy based on molecular testing and PD-L1 status",
          "alternatives": [
            "Targeted therapy for driver mutations",
            "Immunotherapy-chemotherapy combinations",
            "Palliative radiation for symptoms"
          ]
        }
      },
      "evidence_level": "Category 1",
      "references": ["NCCN NSCLC Guidelines 2026"]
    },
    {
      "guideline_id": "GL-NSCLC-002",
      "title": "Molecular Testing in Advanced NSCLC",
      "source": "NCCN/ASCO Joint Guidelines",
      "category": "Diagnostics",
      "keywords": [
        "molecular testing",
        "EGFR",
        "ALK",
        "ROS1",
        "BRAF",
        "PD-L1",
        "biomarker"
      ],
      "recommendation": "All patients with advanced NSCLC (Stage IIIB/IV) should undergo broad molecular testing",
      "required_tests": [
        {
          "marker": "EGFR mutations",
          "importance": "Essential - determines TKI eligibility"
        },
        {
          "marker": "ALK rearrangements",
          "importance": "Essential - determines ALK inhibitor eligibility"
        },
        {
          "marker": "ROS1 rearrangements",
          "importance": "Essential - determines crizotinib/entrectinib eligibility"
        },
        {
          "marker": "BRAF V600E",
          "importance": "Important - determines dabrafenib/trametinib eligibility"
        },
        {
          "marker": "PD-L1 expression",
          "importance": "Essential - helps guide immunotherapy selection"
        },
        {
          "marker": "KRAS G12C",
          "importance": "Important - determines sotorasib eligibility"
        },
        {
          "marker": "MET exon 14 skipping",
          "importance": "Important - determines capmatinib/tepotinib eligibility"
        },
        {
          "marker": "RET fusions",
          "importance": "Important - determines selpercatinib eligibility"
        },
        {
          "marker": "NTRK fusions",
          "importance": "Important - determines larotrectinib/entrectinib eligibility"
        }
      ],
      "timing": "Before initiating first-line systemic therapy",
      "evidence_level": "Category 1",
      "references": [
        "ASCO Molecular Testing Guidelines",
        "NCCN NSCLC Guidelines"
      ]
    },
    {
      "guideline_id": "GL-NSCLC-003",
      "title": "Immunotherapy in NSCLC",
      "source": "NCCN Guidelines",
      "category": "Treatment",
      "keywords": [
        "immunotherapy",
        "pembrolizumab",
        "nivolumab",
        "atezolizumab",
        "PD-1",
        "PD-L1",
        "checkpoint inhibitor"
      ],
      "recommendation": "Immunotherapy is first-line for metastatic NSCLC without driver mutations",
      "regimens": [
        {
          "name": "Pembrolizumab monotherapy",
          "indication": "PD-L1 >= 50%, no EGFR/ALK",
          "monitoring": [
            "irAE assessment every visit",
            "Thyroid function q6-12 weeks"
          ]
        },
        {
          "name": "Pembrolizumab + platinum-based chemotherapy",
          "indication": "Any PD-L1, no EGFR/ALK",
          "monitoring": [
            "irAE assessment",
            "CBC with differential",
            "Metabolic panel"
          ]
        },
        {
          "name": "Nivolumab + ipilimumab",
          "indication": "PD-L1 >= 1%, alternative to pembrolizumab regimens",
          "monitoring": ["irAE assessment - higher risk with combination"]
        }
      ],
      "contraindications": [
        "Active autoimmune disease requiring systemic immunosuppression",
        "Prior organ transplant",
        "Active infection"
      ],
      "evidence_level": "Category 1",
      "references": ["KEYNOTE-024", "KEYNOTE-189", "CheckMate-227"]
    },
    {
      "guideline_id": "GL-NSCLC-004",
      "title": "EGFR-Mutant NSCLC Treatment",
      "source": "NCCN Guidelines",
      "category": "Treatment",
      "keywords": [
        "EGFR",
        "mutation",
        "osimertinib",
        "TKI",
        "targeted therapy"
      ],
      "recommendation": "Osimertinib is preferred first-line for EGFR-mutant advanced NSCLC",
      "mutations_covered": ["Exon 19 deletion", "L858R", "T790M (resistance)"],
      "regimens": [
        {
          "name": "Osimertinib",
          "dose": "80 mg daily",
          "indication": "First-line EGFR-mutant NSCLC",
          "monitoring": [
            "ECG for QTc",
            "LFTs monthly initially",
            "Ophthalmology if visual symptoms"
          ]
        }
      ],
      "resistance_management": "At progression, consider rebiopsy for resistance mechanisms",
      "evidence_level": "Category 1",
      "references": ["FLAURA trial"]
    },
    {
      "guideline_id": "GL-NSCLC-005",
      "title": "Chemotherapy-Induced Nausea and Vomiting (CINV) Prevention",
      "source": "ASCO/NCCN Antiemesis Guidelines",
      "category": "Supportive Care",
      "keywords": [
        "nausea",
        "vomiting",
        "CINV",
        "antiemetic",
        "ondansetron",
        "dexamethasone"
      ],
      "recommendation": "Prophylactic antiemetics should be given based on emetogenic potential of chemotherapy",
      "emetogenic_categories": {
        "High": {
          "agents": ["Cisplatin", "Cyclophosphamide (high dose)"],
          "prophylaxis": [
            "5-HT3 antagonist",
            "NK1 antagonist",
            "Dexamethasone",
            "Consider olanzapine"
          ]
        },
        "Moderate": {
          "agents": ["Carboplatin", "Etoposide", "Cyclophosphamide (low dose)"],
          "prophylaxis": [
            "5-HT3 antagonist",
            "Dexamethasone",
            "+/- NK1 antagonist"
          ]
        },
        "Low": {
          "agents": ["Docetaxel", "Paclitaxel", "Pembrolizumab"],
          "prophylaxis": ["Dexamethasone or 5-HT3 antagonist as needed"]
        }
      },
      "evidence_level": "Category 1",
      "references": ["ASCO Antiemesis Guidelines"]
    },
    {
      "guideline_id": "GL-NSCLC-006",
      "title": "Venous Thromboembolism in Cancer",
      "source": "ASCO/ASH Guidelines",
      "category": "Supportive Care",
      "keywords": [
        "DVT",
        "PE",
        "thrombosis",
        "anticoagulation",
        "enoxaparin",
        "LMWH",
        "DOAC"
      ],
      "recommendation": "Cancer patients have elevated VTE risk; prophylaxis and treatment differ from non-cancer patients",
      "prophylaxis": {
        "hospitalized": "LMWH or UFH recommended for most hospitalized cancer patients",
        "ambulatory": "Consider in high-risk patients receiving chemotherapy (Khorana score >= 2)"
      },
      "treatment": {
        "preferred": "LMWH or DOAC (rivaroxaban, edoxaban, apixaban)",
        "duration": "Minimum 6 months; indefinite if ongoing cancer treatment",
        "special_considerations": "Caution with DOACs in GI/GU malignancies due to bleeding risk"
      },
      "drug_interactions": [
        {
          "drugs": ["Enoxaparin", "Hemoptysis"],
          "warning": "Hold anticoagulation if active bleeding"
        },
        {
          "drugs": ["DOAC", "Strong CYP3A4 inhibitors"],
          "warning": "Dose adjustment may be needed"
        }
      ],
      "evidence_level": "Category 1",
      "references": ["ASCO VTE Guidelines", "CLOT trial", "Hokusai VTE Cancer"]
    },
    {
      "guideline_id": "GL-NSCLC-007",
      "title": "Neutropenia Management in Chemotherapy",
      "source": "ASCO/NCCN Guidelines",
      "category": "Supportive Care",
      "keywords": [
        "neutropenia",
        "G-CSF",
        "filgrastim",
        "pegfilgrastim",
        "febrile neutropenia"
      ],
      "recommendation": "G-CSF prophylaxis recommended when febrile neutropenia risk >= 20%",
      "risk_assessment": {
        "high_risk_regimens": [
          "Dose-dense regimens",
          "Cisplatin/etoposide in SCLC"
        ],
        "patient_factors": [
          "Age > 65",
          "Prior febrile neutropenia",
          "Poor performance status"
        ]
      },
      "management": {
        "primary_prophylaxis": "Pegfilgrastim or filgrastim starting day 2-4 after chemotherapy",
        "secondary_prophylaxis": "After episode of febrile neutropenia",
        "treatment": "Broad-spectrum antibiotics within 60 minutes if febrile and neutropenic"
      },
      "evidence_level": "Category 1",
      "references": ["ASCO G-CSF Guidelines", "EORTC Guidelines"]
    },
    {
      "guideline_id": "GL-NSCLC-008",
      "title": "Malignant Pleural Effusion Management",
      "source": "BTS/ASCO Guidelines",
      "category": "Supportive Care",
      "keywords": [
        "pleural effusion",
        "thoracentesis",
        "pleurodesis",
        "PleurX",
        "dyspnea"
      ],
      "recommendation": "Symptomatic malignant pleural effusions should be drained; recurrent effusions may benefit from indwelling catheter or pleurodesis",
      "management_options": [
        {
          "option": "Therapeutic thoracentesis",
          "indication": "Initial drainage, diagnosis, symptom assessment",
          "notes": "Limit to 1-1.5L per session to avoid re-expansion pulmonary edema"
        },
        {
          "option": "Indwelling pleural catheter (PleurX)",
          "indication": "Recurrent effusion, trapped lung, outpatient management preferred",
          "notes": "Patient/caregiver can drain at home; spontaneous pleurodesis occurs in ~50%"
        },
        {
          "option": "Chemical pleurodesis",
          "indication": "Good lung expansion, life expectancy > 3 months",
          "notes": "Talc most effective; requires chest tube"
        }
      ],
      "evidence_level": "Category 2A",
      "references": ["BTS Pleural Guidelines", "TIME2 trial"]
    },
    {
      "guideline_id": "GL-NSCLC-009",
      "title": "Brain Metastases in NSCLC",
      "source": "NCCN/ASCO Guidelines",
      "category": "Treatment",
      "keywords": [
        "brain metastases",
        "CNS",
        "radiation",
        "SRS",
        "WBRT",
        "steroids"
      ],
      "recommendation": "Management depends on number of metastases, symptoms, and systemic disease control",
      "management": {
        "limited_mets": {
          "option": "Stereotactic radiosurgery (SRS)",
          "indication": "1-4 brain metastases, good performance status"
        },
        "multiple_mets": {
          "option": "Whole brain radiation (WBRT) or best supportive care",
          "indication": "Multiple metastases or poor prognosis"
        },
        "symptomatic": {
          "management": [
            "Dexamethasone 4-8mg daily for edema",
            "Levetiracetam if seizures"
          ]
        },
        "EGFR_mutant": {
          "note": "Osimertinib has good CNS penetration - may defer radiation"
        }
      },
      "evidence_level": "Category 2A",
      "references": ["NCCN CNS Guidelines", "Alliance A071701"]
    },
    {
      "guideline_id": "GL-NSCLC-010",
      "title": "Pain Management in Advanced Cancer",
      "source": "NCCN/WHO Guidelines",
      "category": "Supportive Care",
      "keywords": [
        "pain",
        "opioid",
        "palliative",
        "morphine",
        "hydromorphone",
        "WHO ladder"
      ],
      "recommendation": "Follow WHO analgesic ladder; around-the-clock dosing for continuous pain with PRN for breakthrough",
      "principles": [
        "Assess pain using validated scale (0-10)",
        "By the mouth: oral route preferred when possible",
        "By the clock: scheduled dosing for continuous pain",
        "By the ladder: escalate from non-opioid to weak to strong opioids",
        "Individualize: titrate to effect, no ceiling for opioids in cancer"
      ],
      "common_regimens": [
        {
          "medication": "Morphine",
          "starting_dose": "5-10mg PO q4h (opioid-naive)",
          "conversion": "Oral:IV = 3:1"
        },
        {
          "medication": "Hydromorphone",
          "starting_dose": "0.5-1mg PO q4h or 0.2-0.4mg IV q3h",
          "conversion": "Oral:IV = 5:1"
        },
        {
          "medication": "Oxycodone ",
          "starting_dose": "5-10mg PO q4-6h",
          "conversion": "Equianalgesic to 1.5x morphine"
        }
      ],
      "adjuvants": [
        "NSAIDs for bone pain",
        "Gabapentin/pregabalin for neuropathic",
        "Steroids for inflammation/edema"
      ],
      "evidence_level": "Category 2A",
      "references": ["WHO Cancer Pain Guidelines", "NCCN Adult Cancer Pain"]
    },
    {
      "guideline_id": "GL-DRUG-001",
      "title": "Common Drug Interactions in Oncology",
      "source": "Clinical Pharmacology References",
      "category": "Drug Safety",
      "keywords": [
        "drug interaction",
        "CYP450",
        "warfarin",
        "antifungal",
        "anticonvulsant"
      ],
      "interactions": [
        {
          "drug1": "Pembrolizumab",
          "drug2": "Systemic corticosteroids",
          "severity": "moderate",
          "effect": "High-dose steroids may reduce immunotherapy efficacy",
          "recommendation": "Use lowest effective steroid dose; prednisone <10mg/day generally acceptable"
        },
        {
          "drug1": "Enoxaparin",
          "drug2": "NSAIDs",
          "severity": "high",
          "effect": "Increased bleeding risk",
          "recommendation": "Avoid combination; use acetaminophen for pain if possible"
        },
        {
          "drug1": "Opioids",
          "drug2": "Benzodiazepines",
          "severity": "high",
          "effect": "Increased CNS depression, respiratory depression risk",
          "recommendation": "Use caution; consider dose reduction of both agents"
        },
        {
          "drug1": "Carboplatin",
          "drug2": "Nephrotoxic drugs",
          "severity": "moderate",
          "effect": "Increased nephrotoxicity",
          "recommendation": "Monitor renal function closely; avoid concurrent aminoglycosides if possible"
        },
        {
          "drug1": "Osimertinib",
          "drug2": "Strong CYP3A4 inducers",
          "severity": "high",
          "effect": "Reduced osimertinib levels",
          "recommendation": "Avoid carbamazepine, phenytoin, rifampin; use levetiracetam for seizures"
        },
        {
          "drug1": "Levetiracetam",
          "drug2": "Chemotherapy",
          "severity": "low",
          "effect": "Minimal interactions - preferred anticonvulsant in oncology",
          "recommendation": "First-line choice for seizure prophylaxis in brain metastases"
        }
      ],
      "evidence_level": "Based on pharmacokinetic studies",
      "references": ["UpToDate Drug Interactions", "Lexicomp"]
    }
  ]
}
